Biocon's New Breast Cancer Drug CANMAb to Hit Markets Next Month - The New Indian Express

Biocon's New Breast Cancer Drug CANMAb to Hit Markets Next Month

Published: 20th January 2014 06:00 AM

Last Updated: 20th January 2014 01:56 AM

Biocon has announced a new drug for the treatment of HER2 positive metastatic breast cancer in the country. A biosimilar trastuzumab, CANMAb, developed jointly by Biocon and Mylan, will be the world’s first biosimilar version of Herceptin and will be available in dosages of 150 mg/440 mg from February.

Global sales for Herceptin stood at $6.4 billion in 2012 while in India sales were at $21 million. The drug will be manufactured at Biocon facilities in Bangalore and its price will be around 25% lesser than the current list price of the reference product in India, Biocon said.

The 150 mg formulation will be priced at Rs 19,500 per vial of medicine.

Kiran Mazumdar-Shaw, MD, Biocon said, “Biocon intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with CANMAb, which offers the same level of safety and efficacy as the reference product.” Approximately 1.5 lakh new patients are diagnosed with breast cancer every year out of which 25%, according to Biocon, are HER2 positive.

It acts by interfering with HER2 protein production and stops the growth of cancer cells. It can be administered intravenously once every 3 weeks or on a weekly basis. Both versions of the drug can be stored for 1 month which will reduce underdosing or wastage.

comments powered by Disqus

Disclaimer: We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the NIE editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

Read More

follow us Mobile Site iPad News Hunt Android RSS Tumblr Linekin Pinterest Youtube Google Plus Twitter Facebook